A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.
Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater ...
Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results